Palmitoyl Tripeptide-5

Palmitoyl Tripeptide-5 (INCI: Palmitoyl Tripeptide-5; trade name SYN-COLL; CAS 623172-56-5; PubChem CID 11950477) is a synthetic lipopeptide consisting of the tripeptide sequence Lys-Val-Lys covalently conjugated at its N-terminus to a palmitoyl (C16 fatty acid) chain. Molecular weight is approximately 611.9 Da.

The central mechanism relies on structural mimicry of thrombospondin-1 (TSP-1), an endogenous extracellular matrix glycoprotein. TSP-1 contains a functional motif — related to the sequence Arg-Phe-Lys — that engages the latency-associated peptide (LAP) complex surrounding inactive TGF-beta in the extracellular matrix, displacing it and releasing the active cytokine. Palmitoyl Tripeptide-5 reproduces this activity: the Lys-Val-Lys core binds the LAP complex and promotes liberation of active TGF-beta (Murphy-Ullrich & Poczatek, 2000; DOI 10.1016/s1359-6101(99)00029-5).

Active TGF-beta then binds TGF-beta receptor II on dermal fibroblasts, initiating phosphorylation of SMAD2 and SMAD3. The resulting nuclear SMAD complex transcriptionally upregulates collagen type I (COL1A1, COL1A2) and collagen type III, along with fibronectin. In vitro data cited by the manufacturer also show suppression of matrix metalloproteinase-1 (MMP-1) and MMP-3, the principal collagenases upregulated in chronologically aged and photoaged skin.

• The palmitoyl chain increases lipophilicity, facilitating passive diffusion through the stratum corneum and anchoring the molecule in the oil phase of emulsion formulations. • Optimal peptide stability occurs at pH 5.5–6.5; degradation is reported below pH 4.5 and above pH 7.5.

The clinical evidence for Palmitoyl Tripeptide-5 consists entirely of small, manufacturer-sponsored studies; no large-scale, independently conducted randomized controlled trial has been published in a major peer-reviewed dermatology journal. This is typical of the cosmetic signal-peptide category, and the evidence base should be interpreted accordingly.

The developer (originally Pentapharm, subsequently DSM) conducted a controlled comparative study in 60 healthy volunteers applying 2.5% SYN-COLL cream versus 10% palmitoyl pentapeptide-3 cream and placebo, twice daily for 84 days. Using PRIMOS 3D optical surface profilometry, Palmitoyl Tripeptide-5 significantly reduced average and maximum relief parameters (a proxy for wrinkle depth and density) by approximately 12% relative to placebo, with reported 3.5-fold greater effect than placebo. In a separate in-vivo study of 45 volunteers applying 1% and 2.5% concentrations twice daily for 84 days, wrinkle appearance was reduced by 7% and 12%, respectively, in a concentration-dependent pattern. A subjective self-assessment study in 33 Chinese female volunteers (2.5% for 4 weeks) found 77% reported improved skin firmness and elasticity and 60% reported reduced pore appearance; self-assessment data carry significant bias without blinding.

Trookman et al. (2009), published in the Journal of Clinical and Aesthetic Dermatology, reported a single-center, open-label trial (n=37 women, 3 months) evaluating a multi-ingredient topical product that included Palmitoyl Tripeptide-5 alongside TGF-beta3, hyaluronic acid-filling spheres, and a neuromodulatory peptide. Statistically significant improvements in both fine and coarse periocular and perioral wrinkles were recorded at all post-baseline time points (all P less than 0.0001). The multi-ingredient design prevents attribution of benefit to any single component.

The broad systematic review by Gorouhi and Maibach (2009, PMID 19570099) in the International Journal of Cosmetic Science categorized signal peptides as a class and noted that supporting data derive primarily from industry-sponsored studies with small samples, without independent replication. No ClinicalTrials.gov registrations for Palmitoyl Tripeptide-5 are identifiable at time of writing.

Typical dosage: Topical formulation (daily).

Palmitoyl Tripeptide-5 is used exclusively as a topical cosmetic ingredient; no systemic or injectable form exists or is under investigation.

The commercial ingredient SYN-COLL is supplied as an aqueous glycerin solution with an active peptide content of approximately 900–1,300 ppm (roughly 0.1% pure peptide by weight). Concentrations reported in clinical studies refer to the percentage of the supplied commercial solution incorporated into the finished formulation, not to pure peptide by mass.

• Manufacturer-studied concentrations: 1% and 2.5% SYN-COLL solution in a cream base, applied topically twice daily. These produced 7% and 12% wrinkle reduction, respectively, over 84 days. • Typical range in commercial cosmetic formulations: 0.5% to 3% of the commercial blend (equating to roughly 5–40 ppm pure palmitoyl tripeptide-5 peptide). • Application frequency: once or twice daily, consistent with studied protocols. • Duration: clinical studies ran 4 weeks (minimal, self-report) to 12 weeks (biophysical measurements). • Formulation temperature: must be added below 40°C to preserve peptide integrity. • pH range: formulations should be maintained at pH 5.5–6.5 for optimal stability; incompatible with strongly acidic vehicles (below pH 4.5). • Lyophilized bulk preparations (e.g., 200 mg) are available from research suppliers and are intended for topical compounding research use only, not systemic administration.

This information is educational and reflects concentrations studied in cosmetic research literature. It is not medical advice; use any product containing this ingredient according to its labeled directions and consult a qualified healthcare professional for personalized guidance.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

In commercial multi-peptide formulations, Palmitoyl Tripeptide-5 is commonly paired with palmitoyl tetrapeptide-7, which suppresses interleukin-6-mediated collagen degradation through a distinct mechanism; the rationale is dual-pathway coverage of both collagen synthesis (via TGF-beta) and inflammation-driven breakdown. Palmitoyl tripeptide-1 (GHK-palmitoyl) is another frequent companion, stimulating fibroblasts through a separate copper-binding pathway; this pairing appears in Matrixyl-family commercial blends alongside Palmitoyl Tripeptide-5.

The Trookman et al. (2009) open-label clinical study combined Palmitoyl Tripeptide-5 with recombinant TGF-beta3, hyaluronic acid-filling spheres, and acetyl hexapeptide-3, showing strong aggregate results — though synergistic contribution cannot be separated from the individual components.

The following combinations are reported in formulation guides and community skincare use but lack controlled clinical evidence specific to Palmitoyl Tripeptide-5; they should be regarded as anecdotal: • Hyaluronic acid: complementary humectant for surface hydration alongside structural collagen support. • Niacinamide: barrier reinforcement and brightening alongside collagen stimulation. • L-ascorbic acid (vitamin C): cofactor for collagen prolyl hydroxylase; mechanistically plausible co-ingredient. • Ceramides: a supplier technical document claims a 1.9-fold efficacy enhancement; this has not been independently validated.

Combination with strong AHA or BHA formulations at pH below 4.5 is generally discouraged, as peptide hydrolysis may reduce activity.

Palmitoyl Tripeptide-5 is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Safe for topical use

The Cosmetic Ingredient Review (CIR) Expert Panel published a Safety Assessment of Palmitoyl Oligopeptides as Used in Cosmetics (2012), covering this ingredient class and concluding they are safe for use in leave-on cosmetic products at concentrations employed in commercial formulations. This is the principal regulatory-adjacent safety determination for the compound class.

In available manufacturer-sponsored clinical studies of up to 84 days at concentrations of 1–2.5% of the commercial blend, no treatment-related adverse events were reported. No significant cutaneous irritation, sensitization, phototoxicity, or mutagenicity findings appear in the safety literature.

• The molecular weight of approximately 612 Da, combined with the palmitoyl tail, limits but does not eliminate passive transdermal penetration; systemic exposure from topical cosmetic use is considered negligible. • The compound is listed in the EU COSING database as permitted for skin conditioning in leave-on cosmetic products; it is also used in U.S. cosmetics without regulatory restriction. • EWG and SkinSAFE databases classify the ingredient as low-hazard, with no documented concerns for carcinogenicity, hormone disruption, or developmental toxicity. • Rare user-reported reactions include transient mild warmth or tingling immediately after application, primarily in individuals with sensitive or reactive skin; these are not characterized as adverse events in clinical literature. • Palmitoyl Tripeptide-5 does not carry the irritation, photosensitivity, or barrier disruption risks associated with retinoids, making it a commonly cited alternative for sensitive skin types.

No formal contraindications are established. Safety in pregnancy and lactation has not been evaluated in controlled studies, as is typical for cosmetic peptides. Individuals with known peptide hypersensitivity or contact dermatitis histories should conduct patch testing before prolonged use.